English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 18076/20274 (89%)
造訪人次 : 5356562      線上人數 : 1260
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34114


    標題: Comparing PI3K/Akt Inhibitors Used in Ovarian Cancer Treatment
    作者: Wu, Yi-Hui
    Huang, Yu-Fang
    Chen, Chien-Chin
    Huang, Chia-Yen
    Chou, Cheng-Yang
    貢獻者: Chi Mei Med Ctr, Dept Med Res
    Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Obstet & Gynecol
    Chia Yi Christian Hosp, Dept Pathol, Ditmanson Med Fdn
    Chia Nan Univ Pharm & Sci, Dept Cosmet Sci
    Natl Chiao Tung Univ, Coll Biol Sci & Technol, Dept Biol Sci & Technol
    Cathay Gen Hosp, Gynecol Canc Ctr, Dept Obstet & Gynecol
    Fu Jen Catholic Univ, Sch Med
    關鍵字: epithelial ovarian carcinoma
    chemoresistance
    PI3K inhibitor
    Akt inhibitor
    cisplatin
    paclitaxel
    日期: 2020
    上傳時間: 2022-11-18 11:24:28 (UTC+8)
    出版者: Frontiers Media Sa
    摘要: Epithelial ovarian carcinoma (EOC) is the most lethal gynecological malignancy. Herein, we sought to determine the efficacy of phosphoinositide 3-kinase (PI3K)/Akt inhibition using three AZD compounds in a NOD-SCID xenograft mouse model and Akt regulation in a panel of eight ovarian cancer cell lines. Elevated Akt phosphorylation on Ser473 but not on Thr308 in cancerous tissues correlated with short progression-free survival (PFS), overall survival (OS), and death. AZD8835 and AZD8186 inhibited Akt phosphorylation while AZD5363 augmented its phosphorylation on Ser473. To add, all compounds inhibited the Akt downstream effectors 4E-BP1 and p70S6 kinase. AZD8835 and AZD5363 sensitized chemoresistant ovarian cancer cells to cisplatin and paclitaxel treatment. Only AZD5363 could inhibit COL11A1 mRNA and promoter activity, which are important factors in Akt regulation and chemoresistance in ovarian cancer. By using a mouse xenograft model, AZD8835 and AZD5363, but not AZD8186, caused a significant reduction in tumor formation. AZD compounds did not change the mRNA expression of BRCA1/BRCA in ovarian cancer cells, but AZD8835 inhibited BRCA1/BRCA2 mRNA expression and p-ERK protein expression in OVCAR-8 cells with the KRAS mutation. This study highlights the importance of PI3K/Akt in ovarian tumor progression and chemoresistance and the potential application of AZD compounds, especially AZD8835 and AZD5363, as therapeutic agents for the treatment of ovarian cancer.
    關聯: Frontiers In Pharmacology, v.11, pp.16
    顯示於類別:[化妝品應用與管理系(所)] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    10.3389fphar.2020.00206.pdf4105KbAdobe PDF173檢視/開啟
    index.html0KbHTML387檢視/開啟


    在CNU IR中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋